Second, the investigation of tumor volume and CDI value (0.68) in a syngeneic lung cancer mouse model showed that high-dose AA could act as a promising agent to enhance the antitumor effects of anti-PD1 therapy. This evidence concerns the gene PDCD1 and neoplasm.